Gastrointestinal Cancer News

A new smartphone app called BiliScreen showed promise for pancreatic cancer screening by analyzing signs of jaundice in photos of a user’s eyes.

Epigenomics announced it has begun a post approval study of the blood-based Epi proColon colorectal cancer screening test.

The FDA accepted the resubmission of a new drug application for lutetium Lu 177 dotatate for treatment of adults with unresectable or metastatic, progressive, well-differentiated, somatostatin receptor-positive neuroendocrine tumors.

HemOnc Today presents eight research advances regarding genetic mutations, potential biomarkers and treatment that may be relevant to your practice and help in the management of patients with gastrointestinal cancer.

Patients who chose alternative medicine as their sole cancer therapy had a greater risk for death than those who used conventional cancer treatments, study data showed.

Overall risk for secondary cancers after Kaposi sarcoma decreased over time; however, acute lymphocytic leukemia and cancers of the tongue and penis became new common secondary cancers, according to results of a longitudinal analysis.

Wide area transepithelial sampling with computer-assisted 3-D tissue analysis, or WATS3D, increased the detection of high-grade dysplasia and esophageal adenocarcinoma more than fourfold compared with the standard Seattle protocol random forceps biopsy, according to the results of a pivotal study.

Amid rising cases of oropharyngeal cancer, which are mostly attributable to human papillomavirus, medical care costs for commercially insured patients in Texas were nearly $140,000 — nearly 10 times those of healthy people, according to recently published data.

Prashant Sinha, MD, has been appointed chief of surgery at NYU Langone Hospital-Brooklyn.

Trifluridine and tipiracil in combination with bevacizumab appeared safe and effective for the treatment of patients with metastatic colorectal cancer in the refractory setting, according to results from the C-TASK FORCE study published in The Lancet Oncology.